Drugs / Balixafortide
Balixafortide
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06981806 | Jan 2026 → Feb 2027 expected | pancreatic ductal adenocarcinoma | Arsen Osipov | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT01837095 | Jun 2013 → Aug 2018 | breast cancer | Polyphor Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01841476 | Feb 2012 → Aug 2015 | — | Polyphor Ltd. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04826016 | Mar 2022 | breast cancer | MedSIR | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT01413568 | Apr 2012 → Nov 2015 | B-cell chronic lymphocytic leukemia, acute myeloid leukemia, adult acute lymphoblastic leukemia, chronic myeloid leukemia +2 | Polyphor Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01905475 | Jul 2013 → Oct 2015 | ST-elevation myocardial infarction | Polyphor Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01105403 | Apr 2009 → Feb 2014 | plasma cell myeloma | Polyphor Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03786094 | May 2019 → Oct 2021 | breast cancer | Spexis AG | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | balixafortide | “We assessed the safety, tolerability, pharmacokinetics, and preliminary phase 1 activity of the CXCR4 antagonist, balixafortide, in combination with eribulin chemotherapy in...” PMID 29706375 ↗ Apr 20183“mobilization with a peptidic CXCR4 antagonist POL6326 (balixafortide) vs. G-CSF.” PMID 28049490 ↗ Jan 2017 |
| Known as | Balixafortida | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802129 ↗ |
| Known as | POL6326 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01413568 ↗ |
| Action | Inhibit | “the CXCR4 antagonist” PMID 29706375 ↗ Apr 2018 |
| Modality | Peptide | “a peptidic CXCR4 antagonist POL6326” PMID 28049490 ↗ Jan 2017 |
| Route | Intravenous | “IV infusion of POL6326” NCT01105403 ↗ |
| Target | CXCR4 | “the CXCR4 antagonist” PMID 29706375 ↗ Apr 2018 |